To explore the role of sex hormone-binding globulin (SHBG) in the intracellular steroidal actions in human uterine cervical cancers, the expression of SHBG mRNA as a manifestation of intracellular SHBG expression was investigated using the competitive reverse transcription-polymerase chain reaction-Southern blot analysis. The expression of SHBG mRNA was detected in all cervical endometria and cancers analyzed. The levels of SHBG mRNA in cervical cancers were significantly lower (p < 0.01) than in the normal cervical endometrium. In cervical cancers, the levels of SHBG mRNA in cervical adeno-carcinomas were significantly higher (p < 0.01) than in kera-tinizing and small cell nonkeratinizing squamous cell carcinomas, and tended to be higher than in large cell nonkeratinizing squamous cell carcinomas. There was no difference in expression among the clinical stages of cervical cancers. These data suggest that human uterine cervical cancers, especially ad-enocarcinomas, might synthesize SHBG intracellularly, and might conserve the activity of SHBG-related steroidal mechanisms to some extent.

Keywords:
Sex hormone-binding globulin, mRNA, Uterine cervical cancers
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.